跳至主要内容
临床试验/NCT04403048
NCT04403048Unknown不适用

Rationale and Design of a Prospective, Open Label, Randomized, Multicentric Clinical Trial: Drug Coated Balloon for Side Branch Treatment vs. Conventional Approach in True Bifurcation Coronary Disease: PRO-DAVID

Clinical Hospital Center Rijeka0 个研究点目标入组 800 人开始时间: 2020年10月1日最近更新:
适应症

试验速览

阶段
不适用
发起方
入组人数
800
主要终点
Number of participants who develop major adverse cardiac events

研究概览

简要总结

Bifurcation lesions (BL) on coronary arteries account for 15-20 % of all performed percutaneous coronary interventions (PCI). Preferred approach for treatment of most bifurcation lesions is the stepwise provisional stent strategy with main branch-only stenting followed by provisional balloon angioplasty with or without stenting of the side branch (SB). Stenting of the side branch is indicated when the angiographic result in SB is clearly suboptimal and when flow remains reduced. Upfront use of two stent techniques may be indicated in very complex lesions with large calcified side branches ( most likely to supply at least 10% of fractional myocardial mass), with a long ostial side branch lesion (>5mm) or anticipated difficulty in accessing an important side branch after main branch stenting, and true distal LM bifurcations.

From a technical point of view, we propose a "Provisional DCB approach" that differs from the standard provisional approach with obligatory SB predilation and good lesion preparation. In case of an adequate result of predilation, the procedure on the SB ends with the DCB deployment. This is followed by main branch stenting with DES, finished with POT. Final 'kissing' balloon dilation is generally not recommended because there is no advantage from final kissing with the one-stent technique. With this approach, there is no need for re-wiring, re-ballooning, side branching and wire jailing and final kissing. This technique is close to a contemporary approach to bifurcation lesions based on the fundamental philosophy of the European Bifurcation Club (EBC): keep it simple, systematic, and safe, with a limited number of stents that should be well apposed and expanded with limited overlap, with respect of the original bifurcation anatomy.

详细描述

Bifurcation lesions (BL) on coronary arteries account for 15-20 % of all performed percutaneous coronary interventions (PCI). Preferred approach for treatment of most bifurcation lesions is the stepwise provisional stent strategy with main branch-only stenting followed by provisional balloon angioplasty with or without stenting of the side branch (SB). Stenting of the side branch is indicated when the angiographic result in SB is clearly suboptimal and when flow remains reduced. Upfront use of two stent techniques may be indicated in very complex lesions with large calcified side branches ( most likely to supply at least 10% of fractional myocardial mass), with a long ostial side branch lesion (>5mm) or anticipated difficulty in accessing an important side branch after main branch stenting, and true distal LM bifurcations.

For non-left main bifurcation lesions consensus is that there is no systematic advantage to a more complex dual-stent implantation technique. For true left main lesions EAPCI/EACTS revascularization guidelines gave a IIb recommendation for double-kissing crush two-stent strategy compared to the provisional approach, based on the results of DKCRUSH-V Trial. EBC perspectives, even for the stenting on left main coronary true bifurcation lesions, is that they are best treated with a planned single-stent strategy rather than a planned dual-stent strategy. When a two-stent strategy is used, this will become apparent during a provisional stepwise approach, and finalizing the procedure using a culotte technique or occasionally TAP is recommended.

PCI strategies for complex coronary bifurcation lesions should be individualized, taking into account the anatomical differentiation of coronary bifurcation lesion differences, disease burden and complexity, but also the technical skills and experience of the operator. In daily clinical practice where less experienced operators with limited number of true bifurcations annually are faced with the challenge of treating complex bifurcation lesions, it is imperative to find a standardized and universal approach which would be simple, quick and safe, with a high percentage of procedural success, with a small number of complications, good long term results, with small expenditure of material and contrast volumes, and shorter procedure and fluoroscopy times.

Drug-coated balloon (DCB) technology allows to bring high concentration of an antiproliferative drug with immediate and rapid local delivery even with short contact times between the balloon surface and the vessel wall, sufficient for effective drug delivery without a durable polymer and further permanent metal prosthesis. The application of DCB in SB is an attractive and intriguing solution in treating complex BL. Rationality of such an approach lies in the many theoretical advantages of DCB. The application of DCB in SB respects the original anatomy of bifurcation, which is especially important in the carina area, and allows for the homogeneous application of a high dose of antiproliferative drug on the entire blood vessel surface and avoids the risk of incomplete coverage of the bifurcation area. In the case of a successful DCB application in the SB, unnecessary use of the stent is avoided, obviating long-term problems such as stent malposition and fracturing, scaffolding of the SB ostium, overlapping and crushing of multiple metal layers and polymers with uncontrolled drug release, and therefore re-stenosis and thrombosis and reactions to a foreign body. Even for the simplest provisional technique, the application of DCB has a theoretical advantage over the application of a regular balloon, with the expected positive remodelling of the vessel and plaque stabilization, and better late angiographic results, as well as neoatherosclerosis.

From a technical point of view, we propose a "Provisional DCB approach" that differs from the standard provisional approach with obligatory SB predilation and good lesion preparation. In case of an adequate result of predilation, the procedure on the SB ends with the DCB deployment. This is followed by main branch stenting with DES, finished with POT. Final 'kissing' balloon dilation is generally not recommended because there is no advantage from final kissing with the one-stent technique. With this approach, there is no need for re-wiring, re-ballooning, side branching and wire jailing and final kissing. This technique is close to a contemporary approach to bifurcation lesions based on the fundamental philosophy of the European Bifurcation Club (EBC): keep it simple, systematic, and safe, with a limited number of stents that should be well apposed and expanded with limited overlap, with respect of the original bifurcation anatomy.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patients must meet ALL of the inclusion criteria:
  • stable angina Canadian Cardiovascular Society (CCS) 2 to 4, unstable angina, NSTEMI
  • clinical and anatomic eligibility for PCI as agreed to by the local Heart Team
  • in stable angina: a. ischaemic symptoms, or b. proof of ischemia on nonvasive testing, or c. positive FFR or iFR or d. ( for LMS ) IVUS minimal lumen area <6 mm²
  • patients with mental and logistical conditions for further monitoring
  • patients need to accept clinical monitoring during 3 years and sign a written consent form
  • patients need to be older than 18 years
  • Angiographical:
  • de novo bifurcational lesion with affected side branch (Medina 1,1,1; 1,0,1; 0,1,1)
  • side branch diameter ≥ 2,5 mm
  • LM SB-DS ≥70% and SB lesion length > 5 mm
  • non LM: SB-DS ≥ 90% and SB lesion length > 5 mm
  • side branch length ≥ 73mm
  • for patients with LAD/diagonal BL - Scoring system for diagonal branches (Modified SNuHscore) ≥ 2

排除标准

  • STEMI <72 hours preceding
  • Chronic total occlusion of either vessel
  • SYNTAX score for planned lesions to be treated >32
  • cerebrovascular accident within 6 months, surgical procedure within one week
  • pregnant/nursing women
  • ejection fraction LV< 30%, congestive heart failure, cardiogenic shock or sever valvular disease
  • unfavourable long-term prognosis - patient life expectancy less than 12 months
  • creatinine > 2,0 mg/dl ( 177 mmol/L)
  • hypersensibility, allergies or contraindication to: aspirin, heparin, clopidogrel, prasugel, steel, sirolimus, everolimus, zotarolimus, biolimus or contrast agents
  • treatment of hyperthyroidism, administration of immunosuppressives or anticoagulant therapy, addiction to alcohol or drugs
  • patients included in other clinical trials
  • Angiographical:
  • thrombotic lesions
  • severe calcification
  • patients who have had a stent implanted previously ≤ 15 mm from the current lesions which is included in the study
  • lesions on the aorto-coronary venous or arterial grafts or on chronic total occlusions
  • In-stent restenosis or restenosis in a segment closer than 4 mm from the target lesion

结局指标

主要结局

Number of participants who develop major adverse cardiac events

时间窗: 12 months after the procedure

Defined as cardiac death, myocardial infarction unrelated to the procedure which demanded hospitalization, revascularization of the target lesion

次要结局

  • Number of patients who develop an individual component of the primary endpoint(12 months and 36 months after the procedure)
  • Rate of possible, probable or definitive stent thrombosis(12 months after the procedure)
  • Rate of in segment late lumen loss in any of the treated branches(9 months after the procedure)
  • Rate of "bailout" stenting and inadequate predilatation(immediately after the procedure)
  • Fluoroscopy time(immediately after the procedure)
  • Fluoroscopy dose(immediately after the procedure)
  • Contrast volume(immediately after the procedure)
  • Assessing a composite of the number of guidewires, balloons and stents opened or used(immediately after the procedure)
  • Rate lumen gain difference of 20%(6-9 months after the procedure)
  • Rate of angiographic success(immediately after the procedure)
  • Rate of procedural success(immediately after the procedure)

研究者

发起方
Clinical Hospital Center Rijeka
申办方类型
Other
责任方
Principal Investigator
主要研究者

Deiti Prvulovic

Principal Investigator, MD, PhD

Clinical Hospital Center Rijeka

相似试验

Drug Coated Balloon for Side Branch Treatment vs.... | 临床试验